2024
Novel immunotherapeutics against LGR5 to target multiple cancer types
Chen H, Mueller N, Stott K, Kapeni C, Rivers E, Sauer C, Beke F, Walsh S, Ashman N, O’Brien L, Rafati Fard A, Ghodsinia A, Li C, Joud F, Giger O, Zlobec I, Olan I, Aitken S, Hoare M, Mair R, Serrao E, Brenton J, Garcia-Gimenez A, Richardson S, Huntly B, Spring D, Skjoedt M, Skjødt K, de la Roche M, de la Roche M. Novel immunotherapeutics against LGR5 to target multiple cancer types. EMBO Molecular Medicine 2024, 16: 2233-2261. PMID: 39169164, PMCID: PMC11393416, DOI: 10.1038/s44321-024-00121-2.Peer-Reviewed Original ResearchConceptsHepatocellular carcinomaColorectal cancerTarget multiple cancer typesBispecific T-cell engagerCell killing in vitroChimeric antigen receptorT-cell engagersCancer cells in vitroPre-B-ALLAnti-tumor efficacyCancer cell killing in vitroKilling in vitroCells in vitroAntibody-drug conjugatesMultiple cancer typesLgr5 overexpressionTumor burdenAntigen receptorMurine modelNovel immunotherapeuticsCancer modelsTumor cellsEffective modalityEffective tumorLgr5
2023
Cancer Evolution: A Multifaceted Affair
Ciriello G, Magnani L, Aitken S, Akkari L, Behjati S, Hanahan D, Landau D, Lopez-Bigas N, Lupiáñez D, Marine J, Martin-Villalba A, Natoli G, Obenauf A, Oricchio E, Scaffidi P, Sottoriva A, Swarbrick A, Tonon G, Vanharanta S, Zuber J. Cancer Evolution: A Multifaceted Affair. Cancer Discovery 2023, 14: of1-of13. PMID: 38047596, PMCID: PMC10784746, DOI: 10.1158/2159-8290.cd-23-0530.Peer-Reviewed Original ResearchConceptsEvolutionary mechanismsMultiple evolutionary mechanismsCancer evolutionHeritable genetic changesTumor evolutionImprove personalized medicineEpigenetic reprogrammingGenetic changesTumor microenvironmentGenetic instabilityCancer hallmarksEvolutionary toolkitNongenetic mechanismsCancer cellsPersonalized medicineBiomarker discoveryTumor cellsTumor progressionTumorComprehensive characterizationMolecular modificationsCancerCellsChromatinReprogramming